Raptor Pharmaceutical Corp.

(RPTP) Trade

By |

Profile

Raptor Pharmaceutical Corp was initially incorporated in Nevada on July 29, 1997 as Axonyx Inc. In October 2006, Axonyx Inc. and its then wholly-owned subsidiary completed a reverse merger, business combination with TorreyPines Therapeutics, Inc., reincorporated in Delaware and changed the corporate name to 'TorreyPines Therapeutics, Inc. On September 28, 2009, the Company name was again changed from TorreyPines Therapeutics, Inc., to Raptor Pharmaceutical Corp. It is a biopharmaceutical company focused on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The Company's product PROCYSBI cysteamine bitartrate, delayed-release capsules received marketing approval from the U.S. Food and Drug Administration on April 30, 2013 for the management of nephropathic cystinosis in adults and children six years and older.

Contact Information

Website: www.raptorpharma.com
Email: info@raptorpharma.com
Main Phone: +1 415 408-6200
Address: 7 Hamilton Landing
Address 2: Suite 100
State: CA
City / Town: Novato
Country: USA
Postal Code: 94949

Issuer Information

Exchange: NSD
CEO: Julie Anne Smith
Employees: 158
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

View More

Profile

Raptor Pharmaceutical Corp was initially incorporated in Nevada on July 29, 1997 as Axonyx Inc. In October 2006, Axonyx Inc. and its then wholly-owned subsidiary completed a reverse merger, business combination with TorreyPines Therapeutics, Inc., reincorporated in Delaware and changed the corporate name to 'TorreyPines Therapeutics, Inc. On September 28, 2009, the Company name was again changed from TorreyPines Therapeutics, Inc., to Raptor Pharmaceutical Corp. It is a biopharmaceutical company focused on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The Company's product PROCYSBI cysteamine bitartrate, delayed-release capsules received marketing approval from the U.S. Food and Drug Administration on April 30, 2013 for the management of nephropathic cystinosis in adults and children six years and older.

Contact Information

Website: www.raptorpharma.com
Email: info@raptorpharma.com
Main Phone: +1 415 408-6200
Address: 7 Hamilton Landing
Address 2: Suite 100
State: CA
City / Town: Novato
Country: USA
Postal Code: 94949

Issuer Information

Exchange: NSD
CEO: Julie Anne Smith
Employees: 158
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

View More
(%)
Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size 0.00 Ask N/A Ask Size 0.00
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume 0 52 Wk Hi 9.06 52 Wk Low 2.95
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 85,306,787.00 EPS (TTM) -1.03 PE Ratio N/A Exchange NSD
  Last 3 Mo Last 12 Mo
Number of Insider Trades 0 0
Number of Buys 0 0
Number of Sells 0 0
Net Activity 0 0
Last 10 Buys Shares
Llew Keltner 1,000
Georgia L. Erbez 1,000
Last 10 Sell Shares
Suzanne L. Bruhn 1,000
Raymond William Anderson 1,000
Raymond William Anderson 1,000
Llew Keltner 1,000
Thomas E. Daley 1,000
Thomas E. Daley 1,000
Suzanne L. Bruhn 1,000
Thomas E. Daley 1,000
Richard L. Franklin 1,000
Richard L. Franklin 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 9 9 9 9
Low Target Price Estimate 9 9 9 9
Mean Target Price Estimate 9 9 9 9
Standard Deviation 0 0 0 0
Date of Most Recent Estimate 09/16/16 09/16/16 09/16/16 09/16/16
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 1 1 3 3
Moderate Buy 0 0 0 0
Hold 2 3 2 2
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.33 2.5 1.8 1.8